1
|
Papoutsi M, Dincer Z, Shaw D, Junker U, Bergeron R. Approaches and rationale for the selection of a non-rodent species within a low molecular weight, early drug development program. Toxicol Lett 2015. [DOI: 10.1016/j.toxlet.2015.08.207] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
2
|
Wirz S, Wiese CHR, Zimmermann M, Junker U, Heuser-Grannemann E, Schenk M. [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society]. Schmerz 2014; 27:76-80. [PMID: 23377349 DOI: 10.1007/s00482-013-1292-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The spectrum of indications for rapid release fentanyl preparations is controversial. For this reason the Working Group on Tumor Pain will formulate comments on how to deal with these substances. Breakthrough pain should receive individualized therapy; therefore, the use of opioids of various galenic formulations seems to be advisable. New rapid release fentanyl preparations are suitable for alleviating spontaneous breakthrough pain in tumor patients due to a rapid but short-acting effect. However, a prior optimization of the analgesic basis medication is absolutely necessary. Uncontrolled prescription for non-cancer pain must be criticized due to the problem of addiction. The medical profession should be informed about the benefits of rapid release fentanyl preparations but must also be made aware of the risk of a rapid development of addiction and tolerance. A self-commitment of the pharmaceutical industry to waive advertising for the dangerous off-label use would be desirable. In the opinion of the Working Group on Tumor Pain the use of fentanyl should be openly discussed and further scientific investigations are imperative with the aim of formulating clear recommendations.
Collapse
Affiliation(s)
- S Wirz
- Abteilung für Anästhesie, Interdisziplinäre Intensivmedizin, Schmerztherapie, Palliativmedizin, CURA Kath. Krankenhaus im Siebengebirge, Schülgenstr. 15, 53604, Bad Honnef, Deutschland.
| | | | | | | | | | | |
Collapse
|
3
|
Wirz S, Nadstawek J, Elsen C, Junker U, Wartenberg HC. Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care (Engl) 2011; 21:131-40. [PMID: 21880080 DOI: 10.1111/j.1365-2354.2011.01286.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Constipation and the laxatives polyethylene glycol (PEG), sodium picosulphate (SPS) and lactulose (L) were investigated in outpatients with cancer and on opioid therapy. Randomly selected patients were enrolled in a prospective, controlled, open-label trial. Endpoints were number of patients taking laxatives >28 days, number of patients with a stool-free interval >72 h (sfi72), dosage, numerical rating scale (NRS) for constipation, and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) questionnaire scores. The 348 patients had comparable demographic and medical data. In this ambulatory population, mobility scores remained unaffected. Constipation incidence was 5.7%, with sfi72 42, mean NRS 2.3557 and mean QoL 2.1. A total of 53.2% discontinued their laxative medication. Laxative use correlated with higher opioid usage (morphine-equivalent mg/day: no laxative 98.2, SPS 128.2, PEG 139.9, L 154.5). PEG was the most frequently prescribed laxative (PEG 27.3%, SPS 10.3%, L 9.2%). PEG (sfi72 12.6%, NRS 2.2, QoL 2.1) and SPS (sfi72 11.1%, NRS 2.7, QoL 2.2) proved more effective than L (sfi72 15.5%, NRS 3.8, QoL 2.5). In spite of opioid therapy, the incidence of constipation was low in these ambulatory cancer pain patients at an early disease stage. For prevention of constipation, PEG or SPS is recommended instead of L.
Collapse
Affiliation(s)
- S Wirz
- Department of Anesthesiology, Intensive Care Medicine, Pain Therapy, Palliative Medicine, CURA-Hospital, Schuelgenstrasse 15, Bad Honnef, Germany.
| | | | | | | | | |
Collapse
|
4
|
Junker U, Wirz S. Schmerztherapie in der Lehre – Quo vadis? Schmerz 2011; 25:10-1. [DOI: 10.1007/s00482-011-1015-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
5
|
Abstract
BACKGROUND The subject of pain and pain therapy is not mandatory in medical curricula in Germany. Therefore, the German Society for the Study of Pain (DGSS) has developed a core-curriculum for pain and suggested its implementation for all medical faculties. METHOD At the University of Witten/Herdecke this DGSS core curriculum was extended in terms of a "pain week", which comprised 22 h of seminars and clinical teaching and started in 2009. The knowledge gained by the students regarding the intended learning issues was measured by a pre-post self-assessment questionnaire. RESULTS In almost every category the students reported significant knowledge gain. The learning issues were rated as relevant for the professional career. CONCLUSION The "pain week" is intended to be a constant part of the medical curriculum at the University of Witten/Herdecke in the future. It will be integrated into the new cross-sectional subject of palliative care and be assessed by examinations.
Collapse
Affiliation(s)
- K Gehlhar
- Studiendekanat der Medizinischen Fakultät, Universität Witten/Herdecke, Alfred-Herrhausen-Str. 50, 58448 Witten, Deutschland.
| | | | | | | |
Collapse
|
6
|
Saur P, Junker U, Gaus P, Haeske-Seeberg H, Blöchle C, Neugebauer E. [Implementation of a standardized perioperative pain management concept in three hospitals of a consortium]. Schmerz 2008; 22:34-42. [PMID: 18075761 DOI: 10.1007/s00482-007-0605-9] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Provision of sufficient perioperative pain therapy is an obligation in the clinical management of patients suffering from pain. The implementation of a standardized pain management concept was planned to be introduced in the clinical routine. The results of three hospitals are shown. MATERIAL AND METHODS The concept included tools which gave information about legal aspects and basic fundamentals of pain relief, management modules regarding agreements on the implementation of perioperative pain therapy, instruments to measure pain intensity, assigning accountability and documentation modules. Questionnaires were carried out according to Picker. RESULTS The project revealed that, according to the Picker questionnaire, about 50% of the patients treated in the hospitals had pain, 30-40% still had intensive pain during the stay in hospital and 90% of the patients received pain relief medication within 10 min of the request. More than 78% of the patients thought the hospital staff did their best to relieve the pain and over 92% found the pain treatment adequate. CONCLUSION It was possible to implement a standardized perioperative pain therapy concept in three hospitals of a consortium. Whether an adequate pain relief can be improved with the help of standard measurements and documentation, could not be evaluated in this study.
Collapse
Affiliation(s)
- P Saur
- Regionales Zentrum Anaesthesie, Schmerztherapie, Rettungs- und Intensivmedizin, Sana-Kliniken Lübeck und Ostholstein GmbH, Kronsforder Allee 71-73, 23560, Lübeck, Deutschland.
| | | | | | | | | | | |
Collapse
|
7
|
Freynhagen R, Grond S, Schüpfer G, Hagebeuker A, Schmelz M, Ziegler D, Von Giesen HJ, Junker U, Wagner KJ, Konrad C. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Int J Clin Pract 2007; 61:1989-96. [PMID: 17892468 DOI: 10.1111/j.1742-1241.2007.01589.x] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
AIMS Conventional approaches to the management of neuropathic pain (NeP) often yield unsatisfactory results. We aimed to investigate pregabalin, a gamma-aminobutyric acid (GABA)-analogue, in a wide range of pregabalin naive patients with treatment refractory NeP. METHODS Investigator-initiated, 4-week, open, prospective multicentre study in tertiary care. Pregabalin was prescribed at physicians' discretion based on patients' individual responses and tolerability, with or without concomitant analgesics. Consecutive patients were requested to fill in questionnaires at baseline and after 14 and 28 days with numerical pain rating scales (0, none; 10, worst possible), sleep rating scales, parts of the Brief Pain Inventory, Pain Experience Scale, Short Questionnaire on Current Burden and the SF-12 health-related quality of life scale. RESULTS In 55 patients, the mean pregabalin dose was 142 +/- 26 mg at day 1 and 348 +/- 161 mg at day 28. The mean pain score decreased from 6.5 +/- 1.7 to 5.5 +/- 1.9 at day 14 and to 4.9 +/- 1.8 at day 28 (-24.6%, p < 0.0001). Significant and rapid improvements were noted in the sleep interference score (p < 0.00001), Short Questionnaire on Current Burden (p < 0.01) and SF-12 (somatic score p < 0.001; psychological score p < 0.01). Pregabalin was well tolerated, and only three patients (5%) discontinued treatment prematurely. CONCLUSIONS Our findings suggest that pregabalin is an effective and well-tolerated drug in difficult-to-treat NeP patients under daily clinical practice conditions. A flexible dosing approach appears appropriate to ensure patient compliance and treatment success.
Collapse
Affiliation(s)
- R Freynhagen
- Department of Anaesthesiology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Junker U, Sarnow E, Tilke C. [Tilidine-Naloxone sustained-release tablets for chronic pain associated with musculoskeletal disease]. MMW Fortschr Med 2006; 148:45. [PMID: 17036904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Affiliation(s)
- U Junker
- CA Spezielle Schmerztherapie und Palliativmedizin, Sana Klinikum Remscheid, Burger Str. 211, D-42859 Remscheid
| | | | | |
Collapse
|
9
|
Roth DR, Roman D, Ulrich P, Mahl A, Junker U, Perentes E. Design and evaluation of immunotoxicity studies. ACTA ACUST UNITED AC 2006; 57:367-71. [PMID: 16709448 DOI: 10.1016/j.etp.2006.03.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2006] [Accepted: 03/30/2006] [Indexed: 11/28/2022]
Abstract
The evaluation of potential adverse effects of pharmaceuticals on the immune system is part of the standard drug development procedures and needs to be available prior to the start of phase III clinical trials. Although the histopathological assessment of lymphoid organs/tissues is considered fundamental for the identification and characterization of immunotoxic reactions, additional investigations are now recommended by the European guidelines for repeated-dose toxicity testing of medicinal products in order to achieve an accurate assessment of immune system functionality with regard to immunomodulation. In the present paper, we describe and discuss a study design which permits the investigation of the immune function in a 4-week study in rats following immunization by subcutaneous administration of the T-dependent antigen Keyhole Limpet Hemocynin (KLH). This includes assessment of hematology parameters, titration of KLH-specific antibodies in serum, lymphocyte immunophenotyping in blood, thymus, spleen and lymph nodes, macroscopic pathology and histopathological evaluation of the lymphatic organs/tissues and of the injection sites.
Collapse
Affiliation(s)
- D R Roth
- Novartis Pharma AG, MUT-2881.408, CH 4002 Basel, Switzerland.
| | | | | | | | | | | |
Collapse
|
10
|
Junker U, Figge V. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study]. MMW Fortschr Med 2005; 147 Suppl 3:91-6. [PMID: 16261943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
BACKGROUND Elderly patients (older than 65) do not always receive adequate analgesic treatment, or else they suffer from side effects of the administered opioid. An alternative is oral controlled-release hydromorphone, the efficacy and tolerability of which in patientswith cancer-related pain and pain of other genesis has been confirmed in clinical studies. AIMS AND METHODS A total of 2650 patients (effective group 2412 patients) average age 64.3 +/- 13.4 most of whom suffering from tumor-related (56.2%) or musculoskeletal (49.4%) pain were recruited to a multicenter observational study to investigate controlled-release hydromorphone administered mainly on an ambulatory basis. Pain intensity and quality of life were self-assessed by the patients and recorded in a questionnaire. RESULTS Pain intensity decreased by 64.3% from 7.0 initially to 2.5 at the final examination (0 = no pain, 10 = most severe pain). Quality of life improved by 51.9%. This corresponded to a self-assessed decrease of impairment of quality of life from 45.9 initially to 22.1 at the final examination (0 = no impairment, 70 = most severe impairment). Opioid-type side effects, documented before initiating treatment, decreased appreciably under treatment with hydromorphone. The efficacy and tolerability of the medication, as well as patient compliance, were assessed by the participating physicians as "very good" or "good". CONCLUSIONS Controlled-release, orally administered hydromorphone is well suited for the treatment of elderly patients with severe pain of different etiologies, in particular those with cancer pain. It is both effective and well tolerated, and has an appreciable positive impact on the patient's quality of life.
Collapse
Affiliation(s)
- U Junker
- Leitender Arzt der Abteilung für spezielle Schmerztherapie und Palliativmedizin des Sana Klinikums, Remscheid
| | | |
Collapse
|
11
|
Gerwin N, Pellas T, Junker U, Aigner T. Pathology and Development - Developmental Systems for Target Validation and Drug Screening in Osteoarthritis. ACTA ACUST UNITED AC 2005. [DOI: 10.2174/1567269054867013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
12
|
Junker U, Figge V. [Observational data in elderly pain patients show that fear of opioid therapy is unfounded]. MMW Fortschr Med 2005; 147:43. [PMID: 16041941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Affiliation(s)
- U Junker
- Ltd. Arzt der Abteilung für Spezielle Schmerztherapie und Palliativmedizin Sana Klinikum Remscheid, Remscheid
| | | |
Collapse
|
13
|
Koch I, Baron A, Roberts S, Junker U, Palacay-Ramona M, Masson E, Kay A, Wiedenmann B, Laurent D, Cebon J. Influence of hepatic dysfunction on safety, tolerability, and pharmacokinetics (PK) of PTK787/ZK 222584 in patients (Pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4134] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- I. Koch
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - A. Baron
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - S. Roberts
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - U. Junker
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - M. Palacay-Ramona
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - E. Masson
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - A. Kay
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - B. Wiedenmann
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - D. Laurent
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| | - J. Cebon
- Med Clin for Hepatology and Gastroenterology, Berlin, Germany; CA Pacific Medcl Ctr Research Inst., San Francisco, CA; The Alfred Hosp, Prahran, Australia; Jenapharm GmbH, Jena, Germany; Novartis Pharmaceuticals Corp, East Hanover, NJ; Schering AG, Berlin, Germany; Ludwig Inst for Cancer Research, Heidelberg, Germany
| |
Collapse
|
14
|
Trarbach T, Schleucher N, Tewes M, Seeber S, Junker U, Laurent D, Vanhoefer U, Masson E, Lebwohl D. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer (CRC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3605] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. Trarbach
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| | - N. Schleucher
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| | - M. Tewes
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| | - S. Seeber
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| | - U. Junker
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| | - D. Laurent
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| | - U. Vanhoefer
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| | - E. Masson
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| | - D. Lebwohl
- Univ of Essen Medcl Sch, Essen, Germany; Schering AG, Berlin, Germany; Novartis, East Hanover, NJ
| |
Collapse
|
15
|
Freynhagen VR, Junker U. [Neuropathic pain]. MMW Fortschr Med 2005; 147:40-2. [PMID: 15934587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/02/2023]
Abstract
Neuropathic pain poses a challenge, since there is no consensus on what constitutes optimal management, and current strategies for diagnosing and treating this heterogeneous condition are largely empirical. In the daily routine a neurological examination that includes a sensory examination with some simple bedside-tests often suffices to establish a tentative diagnosis. The author proposes a basic algorithm that may help clinicians to optimize available therapeutic options and improve pain relief and quality of life in patients with this type of pain. Such first-line drugs as antidepressants, anticonvulsants and sustained-release opioids form the basis for a treatment strategy that is appropriate for the individual patient.
Collapse
Affiliation(s)
- Von R Freynhagen
- Klinik für Anaesthesiologie, Leitender Arzt Schmerztherapie, Universitätsklinikum Düsseldorf.
| | | |
Collapse
|
16
|
Schleucher N, Trarbach T, Junker U, Tewes M, Masson E, Lebwohl D, Seeber S, Laurent D, Vanhoefer U. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3558] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- N. Schleucher
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - T. Trarbach
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - U. Junker
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - M. Tewes
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - E. Masson
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - D. Lebwohl
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - S. Seeber
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - D. Laurent
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - U. Vanhoefer
- University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| |
Collapse
|
17
|
Steward WP, Thomas A, Morgan B, Wiedenmann B, Bartel C, Vanhoefer U, Trarbach T, Junker U, Laurent D, Lebwohl D. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3556] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- W. P. Steward
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - A. Thomas
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - B. Morgan
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - B. Wiedenmann
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - C. Bartel
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - U. Vanhoefer
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - T. Trarbach
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - U. Junker
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - D. Laurent
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| | - D. Lebwohl
- Leicester Royal Infirmary, Leicester, United Kingdom; Humboldt-Universitat Berlin, Charite, Germany; University of Essen Medical Center, Essen, Germany; Schering AG, Berlin, Germany; Novartis Pharmaceuticals Corporation, East Hanover, NJ
| |
Collapse
|
18
|
Junker U, Brunnmüller U. [Efficacy and tolerability of gabapentin in the treatment of patients with neuropathic pain. Results of an observational study involving 5620 patients]. MMW Fortschr Med 2003; 145:37. [PMID: 14655505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Affiliation(s)
- U Junker
- Abt. Spezielle Schmerztherapie und Palliativmedizin Sana Klinikum Remscheid GmbH Hans-Potyka-Str. 28, D-42827 Remscheid
| | | |
Collapse
|
19
|
Kaufmann R, Junker U, Schilli-Westermann M, Klötzer C, Scheele J, Junker K. Meizothrombin, an intermediate of prothrombin cleavage potently activates renal carcinoma cells by interaction with PAR-type thrombin receptors. Oncol Rep 2003; 10:493-6. [PMID: 12579295 DOI: 10.3892/or.10.2.493] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
Recently, meizothrombin (MT), an intermediate enzyme in the prothrombin cleavage cascade has been shown to activate cells of a brain tumor cell line by interaction with PAR-1-type thrombin receptors with a potency comparable to that of thrombin. In this study, we investigated the effect of recombinant human MT (rMT) on calcium mobilization in primary cultures established from surgically resected human renal cell carcinomas. Meizothrombin induced very rapidly transient calcium mobilization in RCC cells comparable to that observed with thrombin. RCC cells stimulated with thrombin after rMT challenge were unable to elicit a new calcium response and vice versa. Therefore, rMT and thrombin seem to activate calcium signaling in primary RCC cultures by similar mechanisms including PAR-1- and PAR-3-type thrombin receptors as shown by using PAR-type specific antibodies. Our results demonstrate rMT as a potent activator of human RCC cells suggesting a function of not only thrombin but also of this catalytically active thrombin precursor enzyme in human renal cell carcinoma.
Collapse
Affiliation(s)
- R Kaufmann
- Research Laboratory, Department of General and Visceral Surgery, Institute of Immunology, Medical Faculty at the Friedrich Schiller University Jena, Research Center Lobeda, Germany.
| | | | | | | | | | | |
Collapse
|
20
|
Kaufmann R, Junker U, Junker K, Nuske K, Ranke C, Zieger M, Scheele J. The serine proteinase thrombin promotes migration of human renal carcinoma cells by a PKA-dependent mechanism. Cancer Lett 2002; 180:183-90. [PMID: 12175550 DOI: 10.1016/s0304-3835(01)00870-9] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
In this study, we demonstrated that thrombin activates protein kinase C (PKC), mitogen activated protein kinases (MAP kinases), transcription factor nuclear factor-kappa B (NF-kappa B), and cAMP-dependent protein kinase (PKA) in the human renal carcinoma cell line A-498. In addition, it enhanced the migratory capacity, but had no effect on the proliferation of A-498 cells. The effect of thrombin on migration could be blocked by the PKA inhibitor H-89 but was not influenced by inhibition of PKC, MAP kinases or NF-kappa B. We concluded, that thrombin acts as a regulator on human A-498 renal carcinoma cell migration including PKA.
Collapse
Affiliation(s)
- R Kaufmann
- Department of General and Visceral Surgery, Medical Faculty at the Friedrich Schiller University Jena, Bachstr. 18, 07740 Jena, Germany.
| | | | | | | | | | | | | |
Collapse
|
21
|
Kaufmann R, Junker U, Nuske K, Westermann M, Henklein P, Scheele J, Junker K. PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int J Oncol 2002. [DOI: 10.3892/ijo.20.1.177] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
22
|
Kaufmann R, Junker U, Nuske K, Westermann M, Henklein P, Scheele J, Junker K. PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int J Oncol 2002; 20:177-80. [PMID: 11743661] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023] Open
Abstract
In this study, we report coexpression of proteinase-activated receptor (PAR)-1- and PAR-3-type thrombin receptors in primary cultures obtained from surgically resected specimens of renal cell carcinomas (RCCs). Receptor expression on RNA level was evaluated by using the RT-PCR technique. Results demonstrated the presence of mRNA encoding PAR-1 and PAR-3, but mRNA encoding PAR-4 could not be found in human RCC cells. The expression of PAR-1 and PAR-3 on protein level was investigated with confocal laser fluorescence and freeze-fracture electron microscopy. Both thrombin receptor types were localized on the cell membrane but were also found on intracellular compartments of RCC cells. On the outer cell membrane, clustering of PAR-1 and PAR-3 molecules was partly observed. This is the first study demonstrating presence of both PAR-1 and PAR-3 in human carcinoma cells.
Collapse
Affiliation(s)
- R Kaufmann
- Department of General and Visceral Surgery, Medical Faculty at the Friedrich Schiller University Jena, D-07740 Jena, Germany.
| | | | | | | | | | | | | |
Collapse
|
23
|
Steiner T, Junker U, Salamon A, Nuske K, Schubert J. Differential expression of cytokines and cytokine receptors in renal cell carcinoma. Urol Int 2001; 66:140-4. [PMID: 11316975 DOI: 10.1159/000056593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Modulation of immunomechanisms by tumor cells can be caused by secretion of cytokines. In vitro data are usually gained in culture systems. It is debatable whether these systems are representative of the conditions inside the respective tumor tissues. Immunohistochemical studies of tumor tissue cryostats were compared with those in matched primary renal cell carcinoma tumor cell cultures. Results were correlated with histopathological characteristics and the in vitro cytotoxic effect of autologous tumor infiltrating lymphocytes (TILs). Expression of all studied cytokines and cytokine receptors could be shown in cryostats and cell cultures, but the detection pattern varied individually. The immunohistochemical results in cryostats were in good accordance with those in cell cultures. Expression of TGFbeta1 both in cryostats and cell cultures significantly correlated with the lack of cytotoxic activity of autologous TILs. Representative data can be obtained in tumor culture systems of primary renal cell carcinoma. TGFbeta1 secretion could play an important role in the interactions between tumor and cytotoxic cells.
Collapse
Affiliation(s)
- T Steiner
- Department of Urology, Friedrich Schiller University, Jena, Germany.
| | | | | | | | | |
Collapse
|
24
|
Steiner T, Junker U, Henzgen B, Nuske K, Durum SK, Schubert J. Interferon-alpha suppresses the antiapoptotic effect of NF-kB and sensitizes renal cell carcinoma cells in vitro to chemotherapeutic drugs. Eur Urol 2001; 39:478-83. [PMID: 11306890 DOI: 10.1159/000052489] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Immunochemotherapy (ICT) with interleukin-2 (IL-2) and interferon-alpha (IFNalpha) with a secondary effector (5-fluorouracil, 5 FU) is the only promising treatment for advanced renal cell carcinoma (RCC). With IFNalpha, besides the activation mechanisms of the immunosystem, a direct antitumor effect on tumor cells is expected. MATERIALS AND METHODS NF-kB activity in three permanent cell lines (Hep2, HepG2, HT29) and in primary RCC cell lines was measured after incubation with tumor necrosis factor-alpha (TNFalpha), IFNalpha, IFN-gamma, TNFalpha+IFNalpha, and IFNgamma+TNFalpha, respectively. NF-kB activity and induction of apoptosis by chemotherapeutic drugs (5FU and doxorubicin) were determined in cells transfected with a constitutively active NF-kB p65 or a dominant negative IkB. RESULTS NF-kB signaling induced by TNFalpha is suppressed by IFNalpha and IFNgamma in the permanent cell lines and in the primary RCC tumor cell cultures. In an in vitro ICT model we show that pretreatment of RCC with IL-2 and IFNalpha leads to a diminished NF-kB response to TNFalpha. In certain tumors, this correlates with increased susceptibility to investigated chemotherapeutic drugs as shown by annexin stain and cell elimination. Modulation of the cellular NF-kB state by a constitutively active p65 or a dominant negative IkB mimics this effect. The IkB construct leads to the same effects as IL-2/IFNalpha pretreatment as shown by predominant elimination of the transfected cells from the overall population, while introduction of p65 leads to a partial rescue from the effect of IL-2 and IFNalpha. The described effect, however, applies only to a selection of primary cell cultures. CONCLUSIONS Besides the immunomodulation effects, treatment of RCC with IL-2/IFNalpha leads to a proapoptotic state in certain tumors. The relevant mediator seems to be IFNalpha by suppression of the antiapoptotic effect of NF-kB. These data can provide an experimental base for correlation with real patient outcome after ICT.
Collapse
Affiliation(s)
- T Steiner
- Department of Urology, Friedrich Schiller University, Jena, Germany.
| | | | | | | | | | | |
Collapse
|
25
|
Mosca JD, Hendricks JK, Buyaner D, Davis-Sproul J, Chuang LC, Majumdar MK, Chopra R, Barry F, Murphy M, Thiede MA, Junker U, Rigg RJ, Forestell SP, Böhnlein E, Storb R, Sandmaier BM. Mesenchymal stem cells as vehicles for gene delivery. Clin Orthop Relat Res 2000:S71-90. [PMID: 11039755 DOI: 10.1097/00003086-200010001-00011] [Citation(s) in RCA: 90] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Mesenchymal stem cells contribute to the regeneration of mesenchymal tissues such as bone, cartilage, muscle, ligament, tendon, adipose, and marrow stroma. Transduction of mesenchymal stem cells from species other than humans is required for the development of disease models in which mesenchymal stem cells-based gene delivery is evaluated. Attempts to transduce mesenchymal stem cells from some species with amphotropic retroviral vectors were unsuccessful, leading to comparative mesenchymal stem cells transductions with xenotropic and gibbon-ape leukemia virus envelope-pseudotyped retroviral vectors. Human, baboon, canine, and rat mesenchymal stem cells were transduced optimally with amphotropic vector supernatants. In contrast, sheep, goat, and pig mesenchymal stem cells showed highest transduction levels with xenotropic retroviral vector supernatant, and rabbit mesenchymal stem cells were transduced optimally with gibbon-ape-enveloped vectors. Using a myeloablative canine transplantation model and gene-marked canine mesenchymal stem cells, the biodistribution of infused and ex vivo expanded mesenchymal stem cells were examined. The majority of transduced canine mesenchymal stem cells were found in the bone marrow samples. The current study shows the use of mesenchymal stem cells as a delivery vehicle for gene transfer studies, and validates the feasibility of delivering mesenchymal stem cells to the marrow compartment for stromal regeneration after cancer-associated cytotoxic therapies.
Collapse
Affiliation(s)
- J D Mosca
- Osiris Therapeutics, Inc, Baltimore, MD, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Dumont RA, Car BD, Voitenok NN, Junker U, Moser B, Zak O, O'Reilly T. Systemic neutralization of interleukin-8 markedly reduces neutrophilic pleocytosis during experimental lipopolysaccharide-induced meningitis in rabbits. Infect Immun 2000; 68:5756-63. [PMID: 10992482 PMCID: PMC101534 DOI: 10.1128/iai.68.10.5756-5763.2000] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2000] [Accepted: 07/03/2000] [Indexed: 11/20/2022] Open
Abstract
Interleukin-8 (IL-8) is elevated in the cerebrospinal fluid (CSF) of patients with meningitis and is proposed to participate in subarachnoid-space pleocytosis. However, intracisternal injection of IL-8 into rabbits failed to induce indices typical of meningitis (leukocyte, tumor necrosis factor, or protein accumulation in the CSF or histopathological changes), indicating that merely increasing the CSF level of this chemokine is insufficient to induce inflammation in this anatomical site. IL-8 treatment did not affect inflammatory responses to subsequently intracisternally administered lipopolysaccharide (LPS). IL-8 was chemotactic for rabbit neutrophils in vitro, and subcutaneous injection of IL-8 (diluted in buffer or CSF) proved the in vivo activity of this peptide and suggested the absence of an IL-8 inhibitor in normal rabbit CSF. LPS-dependent pleocytosis was only slightly diminished by intracisternally administered murine anti-rabbit IL-8 monoclonal antibody (MAb) WS-4 but was dramatically reduced by intravenously administered MAb. Therefore, elevated CSF IL-8 levels may contribute to, but cannot solely account for, neutrophil influx into the subarachnoid space during meningitis. However, inhibition of IL-8 activity of the bloodstream side of the blood-brain barrier effectively reduces pleocytosis, indicating a central role of IL-8 in neutrophil influx into CSF during bacterial meningitis. Thus, inhibition of IL-8 is a possible therapeutic target for adjunct treatment of meningitis.
Collapse
Affiliation(s)
- R A Dumont
- Novartis Pharma Limited, CH-4002 Basel, Switzerland
| | | | | | | | | | | | | |
Collapse
|
27
|
Junker U, Haufe CC, Nuske K, Rebstock K, Steiner T, Wunderlich H, Junker K, Reinhold D. Elevated plasma TGF-beta1 in renal diseases: cause or consequence? Cytokine 2000; 12:1084-91. [PMID: 10880255 DOI: 10.1006/cyto.1999.0645] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We previously reported elevated levels of TGF-beta1 in patients with renal carcinoma. Certain aspects led us to ask whether they might be caused by chronic damage to the kidney(s). Here we report on an extended set of patients with various renal diseases, lung cancer, humoral immunodeficiency and controls. For latent TGF-beta1 in plasma, we find that the control, immunodeficiency, lung cancer and kidney transplant groups do not differ significantly (means, 7.0-8.8 ng/ml). Also, acute short-term renal stress (extracorporal lithotrypsy) does not lead to an increase of TGF-beta1. However, the pyelonephritis patients present with levels of 19.0 ng/ml, chronic extracorporal dialysis patients with 15.5 ng/ml, and renal cell carcinoma patients with 22.8 ng/ml. For active TGF-beta1 these findings are exactly recovered. For serum levels, only the renal carcinoma group presents with significantly elevated levels of TGF-beta1. Kidney transplantation seems to normalize TGF-beta1 levels, while in the kidney cancer patients surgery has an effect only in part of the group. We conclude that elevated plasma TGF-beta1 levels are common in at least two chronic renal disease conditions, and that it normalizes with restoration of renal function. It is tempting to speculate that chronic elevation of TGF-beta1 in these patients may be critically involved in these conditions predisposing to renal cancer.
Collapse
Affiliation(s)
- U Junker
- Institute of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Nathan I, Dizdaroglu M, Bernstein L, Junker U, Lee C, Muegge K, Durum SK. Induction of oxidative DNA damage in u937 cells by TNF or anti-Fas stimulation. Cytokine 2000; 12:881-7. [PMID: 10880232 DOI: 10.1006/cyto.1999.0638] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
TNF and Fas signaling pathways are reported to induce mitochondrial damage associated with production of oxygen radicals. We examined whether such radical production elicited detectable nuclear DNA damage in U937 cells following treatment with TNF or with anti-Fas antibodies. Using GC-mass spectroscopy for analysing base oxidation, several oxidized species increased significantly following TNF treatment, whereas anti-Fas resulted in less detectable oxidative damage using this assay. Cytogenetic analysis showed that, in the presence of aphidicolin, which blocks several types of DNA repair, TNF induced extensive chromosomal damage. Aphidicolin also synergized with TNF and anti-Fas in inducing cell death which was prevented by reducing atmospheric oxygen or addition of n -acetyl cysteine, a scavenger of oxygen radicals. Thus, several lines of evidence point to the TNF and Fas pathways inducing extensive oxidative DNA damage and repair, and suggest potential roles for these pathways in mutagenesis and aging.
Collapse
Affiliation(s)
- I Nathan
- Laboratory of Molecular Immunology, National Cancer Institute, Frederick, MD 21702-1201, USA
| | | | | | | | | | | | | |
Collapse
|
29
|
Oberhoffer M, Stonans I, Russwurm S, Stonane E, Vogelsang H, Junker U, Jäger L, Reinhart K. Procalcitonin expression in human peripheral blood mononuclear cells and its modulation by lipopolysaccharides and sepsis-related cytokines in vitro. J Lab Clin Med 1999; 134:49-55. [PMID: 10402059 DOI: 10.1016/s0022-2143(99)90053-7] [Citation(s) in RCA: 220] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Procalcitonin (PCT), the precursor of calcitonin, was recently put forward as a diagnostic marker of systemic bacterial infection and sepsis. The major PCT production site in sepsis still remains unclear. Because of a certain association between increased levels of PCT and leukocyte-derived cytokines during sepsis, we assessed the possible expression of PCT in human peripheral blood mononuclear cells (PBMCs) and the modulation of PCT by lipopolysaccharides (LPS) and various sepsis-related cytokines by reverse transcriptase-polymerase chain reaction (RT-PCR) by using a novel primer set and flow cytometric analysis with intracellular staining with antibodies to the PCT components calcitonin and katacalcin. RT-PCR and flow cytometric analysis demonstrated that PBMCs express PCT both on mRNA and on protein levels. LPS and various proinflammatory cytokines (interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha), IL-2) had pronounced stimulatory effects on the expression of PCT mRNA. Under identical experimental conditions the anti-inflammatory cytokine IL-10 had no effect on the expression of mRNA for PCT. Flow cytometric analysis demonstrated increased intracellular amounts of PCT components after LPS stimulation. Thus we demonstrate for the first time that PCT is expressed in PBMCs. This expression is modulated by bacterial LPS and sepsis-related cytokines. Therefore PBMCs may be among the sources of elevated PCT levels in patients with sepsis.
Collapse
Affiliation(s)
- M Oberhoffer
- Department of Anesthesiology and Intensive Care Medicine and the Institute of Clinical Immunology, Friedrich Schiller University, Jena, Germany
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Junker U. [Treatment with immunoglobulins]. Z Arztl Fortbild Qualitatssich 1999; 93:105-9. [PMID: 10355059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
The application of various formulations of immunoglobulins has become feasible for an impressive array of indications, and the number of available preparations is quite considerable. Nevertheless aside from immunologic/haematologic routine the relation of promise, cost and risk is hard to estimate. This presentation will try to review these factors for certain groups of diseases.
Collapse
Affiliation(s)
- U Junker
- Institut für Klinische Immunologie, Friedrich-Schiller-Universität Jena.
| |
Collapse
|
31
|
Steiner T, Junker U, Wunderlich H, Schubert J. Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6? Anticancer Res 1999; 19:1533-6. [PMID: 10365139] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
Abstract
BACKGROUND Interleukin (IL)-6 can suppress the cisplatin-induced induction of apoptosis in renal cell carcinoma (RCC) in vitro. There are reports on IL-6 secretion by tumor cells. MATERIALS AND METHODS In supermatants of RCC cultures we measured IL-6 levels by a bioassay. In a videomicroscopic microcytotoxicity assay the immunomodulating effect of secreted cytokines on the cytotoxicity of tumor infiltrating lymphocytes (TIL) was studied. RESULTS The IL-6 concentrations in 17 supematants of healthy renal cells tended to be higher than in the supernatants of tumor cell cultures. By immunostaining we detected IL-6 in 3/6 cell cultures from healthy renal tissue, in 12/22 tumor tissue samples, and in 8/18 tumor cultures respectively. Supernatants suppressing cytotoxic activity of TIL showed higher IL-6 concentrations in tendency. Suppression of cytotoxicity could also be induced by adding discrete concentrations of IL-6. CONCLUSIONS IL6 secreted by tumor cells seems to be tumor protecting against cytotoxic TIL. Blocking this mechanism could be an additional approach in immunotherapy of RCC.
Collapse
Affiliation(s)
- T Steiner
- Department of Urology, Friedrich-Schiller-University, Jena, Germany.
| | | | | | | |
Collapse
|
32
|
Kilic M, Flossmann E, Flossmann O, Vogelsang H, Junker U, Chaouat G, Markert UR. Jeg-3 human choriocarcinoma-induced immunosuppression: downregulation of interleukin-2, interleukin-2 receptor alpha-chain, and its Jak/Stat signaling pathway. Am J Reprod Immunol 1999; 41:61-9. [PMID: 10097788 DOI: 10.1111/j.1600-0897.1999.tb00076.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
PROBLEM The mechanisms of the immunosuppressive and immunosuppression-inducing capacities of Jeg-3 human choriocarcinoma cell line supernatants (HCSs) are not yet completely understood. The influence on interleukin (IL)-2, IL-4 and interferon (IFN)-gamma production; IL-2 receptor (IL-2R) alpha-, beta-, and gamma-chain; and the signaling pathway molecules Janus kinase (Jak)1, Jak3, signal transducers and activators of transcription (Stat)1, Stat3, and Stat5 should be investigated. METHOD OF STUDY For assessment of IL production, whole peripheral venous blood from healthy donors was stimulated with phorbol-myristate-acetate and ionomycine. Secretion of ILs was blocked with monensine. Intracellular ILs were analyzed by flow cytometry. For IL-2R and signaling pathway molecule analysis, peripheral blood lymphocytes were stimulated with phytohemagglutinin (PHA). IL-2R chains were measured by flow cytometry, and Jaks/Stats by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot. RESULTS Phorbol-myristate-acetate and ionomycine strongly increase the percent-age of IL-2+ cells; an additional 50% HCSs significantly suppresses the percentage to, or below the level of unstimulated cells. IFN-gamma production is strongly decreased by HCSs in some cases, but not in others. PHA stimulates IL-2R alpha-, beta-, and gamma-chain expression and their signaling pathway molecules Jak1, Jak3, Stat1, Stat3, and Stat5. 50% HCS downregulates the alpha-chain and slightly upregulates the beta-chain. Jak1, Jak3, Stat1, Stat3, and Stat5 expression is suppressed approximately to, or below the level of unstimulated cells. CONCLUSIONS HCS forcefully blocks the production of IL-2; the IL-2R alpha-chain; and Jak1, Jak3, Stat1, Stat3, and Stat5 expression. The observed phenomena might be caused by downregulation of an IL-2R regulation gene, and might play a key role in the expansion of choriocarcinoma, and possibly in the survival of the fetal allograft.
Collapse
Affiliation(s)
- M Kilic
- Institut für Klinische Immunologie, Friedrich-Schiller-Universität, Jena, Germany
| | | | | | | | | | | | | |
Collapse
|
33
|
Berlau J, Junker U, Groh A, Straube E. In situ hybridisation and direct fluorescence antibodies for the detection of Chlamydia trachomatis in synovial tissue from patients with reactive arthritis. J Clin Pathol 1998; 51:803-6. [PMID: 10193319 PMCID: PMC500970 DOI: 10.1136/jcp.51.11.803] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Chlamydia trachomatis is associated with Reiter's syndrome and reactive arthritis but the form in which the organism survives in synovial cells is unclear. AIM To compare in situ hybridisation with direct fluorescence in the detection of inapparent chlamydial infection in synovial tissue. METHODS Synovial tissue from four patients with reactive arthritis patients was examined using biotin labelled probes for chlamydial DNA and fluorescein isothiocyanate (FITC) labelled monoclonal antibodies against the major outer membrane protein. RESULTS In two of the four patients, evidence of chlamydial infections was detected by in situ hybridisation in parallel sections but not with FITC labelled monoclonal antibodies. CONCLUSIONS Detection of chlamydial DNA by in situ DNA hybridisation may be a better way to identify chlamydial infection in synovial tissue than phenotype targeting with FITC conjugated antibodies, which is used as a standard procedure for screening clinical specimens for chlamydia.
Collapse
Affiliation(s)
- J Berlau
- Institute of Medical Microbiology, University of Jena, Germany
| | | | | | | |
Collapse
|
34
|
Wunderlich H, Steiner T, Kosmehl H, Junker U, Reinhold D, Reichelt O, Zermann DH, Schubert J. Increased transforming growth factor beta1 plasma level in patients with renal cell carcinoma: a tumor-specific marker? Urol Int 1998; 60:205-7. [PMID: 9701731 DOI: 10.1159/000030255] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
PURPOSE The most worrying problem with renal cell carcinoma (RCC) seems to be the prediction of metastases by means of tumor-specific markers. Therefore, much effort is committed to the development of new markers. MATERIALS AND METHODS The level of latent transforming growth factor beta1 (TGF-beta1) was measured in plasma samples by ELISA. These samples were collected from patients with RCC before they underwent radical nephrectomy, from patients 1 h after extracorporeal lithotripsy, from patients with pyelonephritis, and from healthy controls. RESULTS In all cases of RCC the levels of latent TGF-beta1 in plasma were much higher (n = 20, 41.0 +/- 13.9 ng/ml, range 19.3-78.1 ng/ml) than in healthy controls (n = 20, 3.8 +/- 2.9 ng/ml, range 0.6-9.9 ng/ml, p < 0.0001). The TGF-beta1 levels in plasma after extracorporeal lithotripsy (n = 20, 7.4 +/- 4. 64 ng/ml, range 2.9-21.7 ng/ml, p < 0.01) and in patients suffering from pyelonephritis (n = 20, 18.93 +/- 14.2 ng/ml, range 4.2-46.7 ng/ml, p < 0.001) were also higher than in healthy controls. CONCLUSION We conclude that increased levels of latent TGF-beta1 are common in the plasma of RCC patients. The TGF-beta1 plasma level in RCC was found to be significantly higher than in cases of inflammation. Thus, TGF-beta1 is a possible tumor-prognostic marker in RCC.
Collapse
Affiliation(s)
- H Wunderlich
- Department of Urology, Friedrich Schiller University, Jena, Germany
| | | | | | | | | | | | | | | |
Collapse
|
35
|
Steiner T, Junker U, Wunderlich H, Knöfel B, Schlichter A, Schubert J. [Lymphocyte transformation test (LTT) as a model for evaluating cytokine-induced immunomodulation in renal cell carcinoma]. Urologe A 1998; 37:294-8. [PMID: 9646428 DOI: 10.1007/s001200050187] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
We investigated the immunomodulatory capacity of cytokines produced by renal cell carcinoma in vitro by analyzing their effects on mitogen-induced T-lymphocyte blast cell transformation. All of the tested 70 cell cultures, derived from 70 tumor areas in 33 patients, had immunomodulatory capacity. In addition to suppression in the lymphocyte transformation test (max. 44/70; 63%) there was also superinduction (max. 37/70; 53%). We found no significant correlation with the stage and grade of primary tumors. However, the suppression of mitogen-induced T-lymphocyte blast cell transformation was significant in multifocal tumors (0.08% TCM, P < 0.001) and non-significant in metastatic tumors. The production of the assayed cytokines IL-6, IL-10, IL-11, and TGF beta 1 was variable and there was no significant correlation to the immunomodulatory capacity of the tumors.
Collapse
Affiliation(s)
- T Steiner
- Klinik und Poliklinik für Urologie, Friedrich-Schiller-Universität Jena
| | | | | | | | | | | |
Collapse
|
36
|
Veres G, Junker U, Baker J, Barske C, Kalfoglou C, Ilves H, Escaich S, Kaneshima H, Böhnlein E. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J Virol 1998; 72:1894-901. [PMID: 9499041 PMCID: PMC109480 DOI: 10.1128/jvi.72.3.1894-1901.1998] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
The antiviral activities of intracellularly expressed antisense RNAs complementary to the human immunodeficiency virus type 1 (HIV-1) pol, vif, and env genes and the 3' long terminal repeat (LTR) sequence were evaluated in this comparative study. Retroviral vectors expressing the antisense RNAs as part of the Moloney murine leukemia virus LTR promoter-directed retroviral transcript were constructed. The CD4+ T-cell line CEM-SS was transduced with retroviral constructs, and Northern blot analyses showed high steady-state antisense RNA expression levels. The most efficient inhibition of HIV-1 replication was observed with the env antisense RNA, followed by the pol complementary sequence, leading to 2- to 3-log10 reductions in p24 antigen production even at high inoculation doses (4 x 10(4) 50% tissue culture infective doses) of the HIV-1 strain HXB3. The strong antiviral effect correlated with a reduction of HIV-1 steady-state RNA levels, and with intracellular Tat protein production, suggesting that antisense transcripts act at an early step of HIV-1 replication. A lower steady-state antisense RNA level was detected in transduced primary CD4+ lymphocytes than in CEM-SS cells. Nevertheless, replication of the HIV-1 JR-CSF isolate was reduced with both the pol and env antisense RNA. Intracellularly expressed antisense sequences demonstrated more pronounced antiviral efficacy than the transdominant RevM10 protein, making these antisense RNAs a promising gene therapy strategy for HIV-1.
Collapse
Affiliation(s)
- G Veres
- Systemix Inc., a Novartis Company, Palo Alto, California 94304, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Junker U, Kalfoglou CS, Moon JJ, Beck MK, Kaneshima H, Böhnlein E. Inhibition of human immunodeficiency virus type 1 replication in myelomonocytic cells derived from retroviral vector-transduced peripheral blood progenitor cells. Hum Gene Ther 1998; 9:333-40. [PMID: 9508051 DOI: 10.1089/hum.1998.9.3-333] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Monocytes and macrophages (Mo/Mphi) contribute to the pathogenesis of human immunodeficiency virus type 1 (HIV-1) infection. A successful hematopoietic stem/progenitor cell (HSPC)-based gene therapy strategy for HIV-1 disease must protect Mo/Mphi as well as T cells from HIV-1-related pathology. In this report, we demonstrate that RevM10-transduced HSPCs isolated from cytokine-mobilized peripheral blood give rise to Mo/Mphi suppressing replication of Mphi-tropic HIV-1 isolates. A Moloney murine leukemia virus (MoMLV)-based retroviral vector encoding a bicistronic mRNA co-expressing RevM10 and the murine CD8alpha' chain (Lyt2) was used to transduce HSPCs. Following transduction, these cells were expanded and differentiated by short-term culture in methylcellulose containing various cytokines. In vitro differentiated Mo/Mphi were enriched by fluorescence activated cell sorting (FACS) for the co-expressed transgene (Lyt2) and myelomonocytic (CD33, CD14) surface markers. HIV-1 replication of two Mphi-tropic isolates (JR-FL, BaL) was inhibited in Mo/Mphi expressing RevM10 and Lyt2 relative to control cells expressing only Lyt2 but no functional RevM10 gene product. Cell proliferation and expression of lineage-specific surface markers was not altered in transduced, in vitro differentiated Mo/Mphi cells. This study supports the feasibility of HSPC-based gene therapy as a future treatment for HIV-1 disease.
Collapse
Affiliation(s)
- U Junker
- Systemix, Inc., Palo Alto, CA 94304, USA
| | | | | | | | | | | |
Collapse
|
38
|
Junker U, Knoefel B, Nuske K, Rebstock K, Steiner T, Wunderlich H, Junker K, Reinhold D. Transforming Growth Factor Beta 1 is Significantly Elevated in Plasma of Patients Suffering From Renal Cell Carcinoma. J Urol 1998. [DOI: 10.1016/s0022-5347(01)63911-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Affiliation(s)
- U. Junker
- Institute of Clinical Immunology, Clinic for Urology, Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Thueringen-Krankenhaus Saalfeld “Agricola-Krankenhaus,” Saalfeld and Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto-v.-Guericke-University, Magdeburg, Germany
| | - B. Knoefel
- Institute of Clinical Immunology, Clinic for Urology, Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Thueringen-Krankenhaus Saalfeld “Agricola-Krankenhaus,” Saalfeld and Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto-v.-Guericke-University, Magdeburg, Germany
| | - K. Nuske
- Institute of Clinical Immunology, Clinic for Urology, Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Thueringen-Krankenhaus Saalfeld “Agricola-Krankenhaus,” Saalfeld and Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto-v.-Guericke-University, Magdeburg, Germany
| | - K. Rebstock
- Institute of Clinical Immunology, Clinic for Urology, Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Thueringen-Krankenhaus Saalfeld “Agricola-Krankenhaus,” Saalfeld and Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto-v.-Guericke-University, Magdeburg, Germany
| | - T. Steiner
- Institute of Clinical Immunology, Clinic for Urology, Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Thueringen-Krankenhaus Saalfeld “Agricola-Krankenhaus,” Saalfeld and Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto-v.-Guericke-University, Magdeburg, Germany
| | - H. Wunderlich
- Institute of Clinical Immunology, Clinic for Urology, Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Thueringen-Krankenhaus Saalfeld “Agricola-Krankenhaus,” Saalfeld and Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto-v.-Guericke-University, Magdeburg, Germany
| | - K. Junker
- Institute of Clinical Immunology, Clinic for Urology, Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Thueringen-Krankenhaus Saalfeld “Agricola-Krankenhaus,” Saalfeld and Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto-v.-Guericke-University, Magdeburg, Germany
| | - D. Reinhold
- Institute of Clinical Immunology, Clinic for Urology, Institute of Human Genetics and Anthropology, Friedrich-Schiller-University, Jena, Thueringen-Krankenhaus Saalfeld “Agricola-Krankenhaus,” Saalfeld and Institute of Experimental Internal Medicine, Center of Internal Medicine, Otto-v.-Guericke-University, Magdeburg, Germany
| |
Collapse
|
39
|
Oberhoffer M, Russwurm S, Stonans I, Stonane E, Vogelsang H, Junker U, Jäger L, Reinhart K. Human peripheral blood mononuclear cells express mRNA for procalcitonin; modulation by lipopolysaccharides and sepsis related cytokines. Crit Care 1998. [PMCID: PMC3301277 DOI: 10.1186/cc165] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
40
|
Reinhold D, Bank U, Bühling F, Junker U, Kekow J, Schleicher E, Ansorge S. A detailed protocol for the measurement of TGF-beta1 in human blood samples. J Immunol Methods 1997; 209:203-6. [PMID: 9461336 DOI: 10.1016/s0022-1759(97)00160-9] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Quantification of the multifunctional cytokine Transforming Growth Factor-beta1 (TGF-beta1) in blood samples has aroused increasing interest in recent years, since an abnormal regulation of this cytokine appears to play a key role in the pathogenesis of different diseases, such as autoimmundiseases or malignant tumors. The measurement of TGF-beta1 is complicated by a lot of problems concerning the collection, preparation and handling of blood samples, the platelet contamination, and the TGF-beta1 activation procedure. Here, we recommend detailed instructions for measurement of TGF-beta1 in blood plasma samples which should be followed to exclude the determination of false positive or negative results.
Collapse
|
41
|
Junker U, Baker J, Kalfoglou CS, Veres G, Kaneshima H, Böhnlein E. Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1997; 13:1395-402. [PMID: 9359659 DOI: 10.1089/aid.1997.13.1395] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Gene therapy for the treatment of human immunodeficiency virus type 1 (HIV-1) infection using intracellular immunization strategies is currently being tested in clinical trials. With the continuing development of potent antiretroviral drugs (e.g., reverse transcriptase [RT] and protease [PR] inhibitors), it is likely that HIV-1 gene therapy will be applied to humans concurrently receiving such antiretroviral medication. In this study, we assessed the in vitro antiviral efficacy of two gene therapy strategies (trans-dominant RevM10, Gag antisense RNA) in combination with clinically relevant RT (AZT, ddC) or PR (indinavir) inhibitors. Retrovirally transduced, human T cell lines expressing antiviral gene constructs were inoculated with high doses of HIV-1HXB3 in the presence or absence of inhibitors. The combination of RevM10 or Gag antisense RNA with antiviral drugs inhibited HIV-1 replication 10-fold more effectively than the single antiviral drug regimen alone. More importantly, we also addressed whether gene therapy strategies are effective against drug-resistant HIV-1 isolates. Both the RevM10 and Gag antisense RNA strategies showed antiviral efficacy against several RT inhibitor-resistant HIV-1 isolates equivalent to their inhibition of HIV-1HXB3 replication. In summary, our data demonstrate the greater than additive antiviral efficacy of gene therapy strategies and RT or PR inhibitors, and that gene therapy approaches are effective against drug-resistant HIV-1 viral isolates.
Collapse
MESH Headings
- Acquired Immunodeficiency Syndrome/therapy
- Anti-HIV Agents/therapeutic use
- Cell Line
- Combined Modality Therapy
- DNA, Recombinant
- Dose-Response Relationship, Drug
- Gene Products, gag/genetics
- Gene Products, gag/physiology
- Gene Products, rev/genetics
- Gene Products, rev/physiology
- Genetic Therapy
- Genetic Vectors/genetics
- Genome, Viral
- HIV Core Protein p24/drug effects
- HIV Core Protein p24/metabolism
- HIV-1/drug effects
- HIV-1/genetics
- HIV-1/growth & development
- Humans
- Indinavir/therapeutic use
- RNA, Antisense/genetics
- RNA, Antisense/physiology
- T-Lymphocytes/cytology
- T-Lymphocytes/drug effects
- T-Lymphocytes/virology
- Zalcitabine/administration & dosage
- Zalcitabine/therapeutic use
- Zidovudine/administration & dosage
- Zidovudine/therapeutic use
- rev Gene Products, Human Immunodeficiency Virus
Collapse
Affiliation(s)
- U Junker
- Progenesys Program, Systemix Inc., Palo Alto, California 94304, USA.
| | | | | | | | | | | |
Collapse
|
42
|
Junker U, Moon JJ, Kalfoglou CS, Sniecinski I, Forman SJ, Zaia JA, Kaneshima H, Böhnlein E. Hematopoietic potential and retroviral transduction of CD34+ Thy-1+ peripheral blood stem cells from asymptomatic human immunodeficiency virus type-1-infected individuals mobilized with granulocyte colony-stimulating factor. Blood 1997; 89:4299-306. [PMID: 9192752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
The potential of hematopoietic stem cells (HSCs) from human immunodeficiency virus type-1 (HIV-1)-infected individuals, eg, self-renewal and multilineage differentiative capacity, might be perturbed due to the underlying disease. In this study, we assessed the HSC activity in the CD34+ Thy-1+ cell population of peripheral blood stem cells (PBSCs) of three asymptomatic HIV-1-infected individuals after granulocyte colony-stimulating factor (G-CSF; 10 microg/kg/d) mobilization. On day 4 of G-CSF treatment, 0.8% to 1% of the total blood mononuclear cells were CD34+. Leukapheresis followed by a two-step cell isolation process yielded a CD34+ Thy-1+ cell population of high purity (76% to 92% CD34+ Thy-1+ cells). This cell population showed no evidence of HIV-1-containing cells based on a semiquantitative HIV-1 DNA polymerase chain reaction. Furthermore, the purified cells showed normal hematopoietic potential in in vitro clonogenic assays. Successful gene transfer into committed progenitor cells (colony-forming units-cells) and more primitive stem/progenitor cells (long-term culture colony-forming cells) could be shown after amphotropic retroviral transduction. These data provide evidence that the CD34+ Thy-1+ stem cell compartment can be mobilized and enriched in early stage HIV-1-infected patients. Furthermore, successful transduction of this cell population as a prerequisite for stem cell-based clinical gene therapy protocols was demonstrated.
Collapse
Affiliation(s)
- U Junker
- Progenesys Program, Systemix Inc, Palo Alto, CA 94304, USA
| | | | | | | | | | | | | | | |
Collapse
|
43
|
Wunderlich H, Steiner T, Junker U, Knöfel B, Schlichter A, Schubert J. Serum transforming growth factor-beta1 in patients with renal cell carcinoma. J Urol 1997; 157:1602-3. [PMID: 9112485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
PURPOSE A major problem of renal cell carcinoma is the prediction of metastases via tumor prognostic markers. Therefore, much effort has been committed to the development of new prognostic markers. MATERIALS AND METHODS The level of transforming growth factor-beta1 was measured by enzyme-linked immunosorbent assay in serum samples collected from patients with renal cell carcinoma before radical nephrectomy. RESULTS In serum samples from 21 patients with renal cell carcinoma and 21 healthy controls mean transforming growth factor-beta1 levels were 177 +/- 54.1 versus 65.6 +/- 15.8 ng./ml., respectively. This difference was statistically significant (Mann-Whitney U test p <0.001). CONCLUSIONS Increased levels of transforming growth factor-beta1 are common in serum of patients with renal cell carcinoma.
Collapse
Affiliation(s)
- H Wunderlich
- Department of Urology and Institut of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany
| | | | | | | | | | | |
Collapse
|
44
|
Vogl S, Junker U, Vogelsang H, Dargel R. Macrophages from rat livers with micronodular and macronodular cirrhosis differ with respect to mediator release and DNA-synthesis. J Hepatol 1997; 26:1093-103. [PMID: 9186840 DOI: 10.1016/s0168-8278(97)80118-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND/AIMS Liver macrophages play an essential role in necro-inflammatory liver damage which leads to fibrosis and cirrhosis. The aim of the present study was to compare the mediator release and the DNA synthesis of macrophages at an early and at a later stage of liver cirrhosis induced by thioacetamide. METHODS Liver macrophages were isolated by an enzymic digestion method, followed by elutriation. The release of reactive oxygen species and cytokines, and the synthesis of DNA were measured in cultivated cells. RESULTS The vitality of isolated macrophages from cirrhotic livers was always higher than 98%. The total yield of macrophages was less in micronodular cirrhotic livers and was markedly higher in macronodular cirrhotic livers when compared with age-matched controls. The cellular granules measured by sideward light scattering showed a shift to larger sizes in macrophages from micronodular cirrhotic livers when compared with the controls and the other experimental group. Macrophages from both cirrhosis groups exhibited a markedly higher unstimulated and lipopolysaccharide-stimulated IL-6 production than the controls. The release of TNF-alpha did not differ between controls and the experimental groups. Macrophages from macronodular cirrhotic livers produced higher amounts of nitric oxide but less superoxide anion radicals than the controls. DNA synthesis was 10-12-fold and 3-10-fold higher in macrophages from micronodular and macronodular cirrhotic livers, respectively, when compared with the age-matched controls. CONCLUSIONS The data presented provide evidence that it is possible to isolate and to cultivate macrophages from livers with high yield and vitality at different stages of cirrhogenesis. Our results clearly demonstrate functional differences between macrophages from livers with micro- or macronodular cirrhosis; this finding may be important for the pathogenesis or perpetuation of the cirrhogenetic process.
Collapse
Affiliation(s)
- S Vogl
- Institute of Pathobiochemistry, Medical Faculty of Friedrich Schiller University Jena, Germany
| | | | | | | |
Collapse
|
45
|
Affiliation(s)
- H. Wunderlich
- From the Department of Urology and Institut of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany
| | - T. Steiner
- From the Department of Urology and Institut of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany
| | - U. Junker
- From the Department of Urology and Institut of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany
| | - B. Knofel
- From the Department of Urology and Institut of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany
| | - A. Schlichter
- From the Department of Urology and Institut of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany
| | - J. Schubert
- From the Department of Urology and Institut of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany
| |
Collapse
|
46
|
Junker K, Schlichter A, Junker U, Knöfel B, Kosmehl H, Schubert J, Claussen U. Cytogenetic, histopathologic, and immunologic studies of multifocal renal cell carcinoma. Cancer 1997; 79:975-81. [PMID: 9041160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
BACKGROUND Multifocal tumor areas occurred in 12-22% of patients with renal cell carcinoma. It is unknown whether these tumors have malignant potential and characterize a higher risk for metastases. The performance of nephron-sparing surgery in patients with low grade or low stage tumors is controversial. METHODS Primary and secondary tumors were analyzed by conventional cytogenetics and fluorescence in situ hybridization. Production of interleukin (IL)-6, IL-10, IL-11, and transforming growth factor (TGF)-beta1 were determined using standard enzyme-linked immunosorbent assay and bioassays. RESULTS In 15.2% of the renal cell carcinoma cases evaluated, multifocal tumors were detected. Cytogenetics revealed a concordance of primary and secondary tumors in 9 of 14 cases (64%). In 11 of 12 multifocal tumors (94%), the same immunologic activity status was observed in both primary and secondary tumors. CONCLUSIONS Secondary tumors must be expected to have malignant potential similar to that of the primary tumors. This was underscored by the high concordance of cytogenetic, histopathologic, and immunologic data in this study.
Collapse
Affiliation(s)
- K Junker
- Institute of Human Genetics and Anthropology, Friedrich Schiller University, Jena, Germany
| | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Flow cytometry was used to quantify the transmembrane anion exchanger (band 3 protein) of human erythrocytes by covalently bound eosin-5-maleimide. In vitro and in vivo vesiculated red blood cells were investigated. The fluorescence and light scatter signals of cells after heat induced vesiculation, in vivo ageing, and in patients with hereditary spherocytosis were decreased. These results reflect a deficiency of band 3 protein which is presumably caused by membrane surface area loss. It was possible to distinguish control erythrocytes, erythrocytes from patients with hereditary spherocytosis, and from other forms of haemolytic anaemias on the basis of their light scatter and fluorescence signals characteristics.
Collapse
Affiliation(s)
- G Stoya
- Institute of Anatomy I, Friedrich Schiller University Jena, Germany
| | | | | | | | | |
Collapse
|
48
|
Knoefel B, Nuske K, Steiner T, Junker K, Kosmehl H, Rebstock K, Reinhold D, Junker U. Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 1997; 17:95-102. [PMID: 9058315 DOI: 10.1089/jir.1997.17.95] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
We investigated the immunomodulatory capacity of primary cultures of renal cell carcinomas (RCC) by assessing production of cytokines and modulation of mitogen-induced T lymphocyte blast transformation. The results clearly show that immunomodulatory capacity is a common feature of RCC and that in vitro these tumors can produce interleukin-10 (IL-10) up to 20 ng/ml, IL-6 up to 35 micrograms/ml (> 250 kU/ml in the B9 system), IL-11 up to 15 micrograms/ml, and transforming growth factor-beta 1 (TGF-beta 1) up to 22 ng/ml. Furthermore, these tumors have the capacity to modulate T cell blast transformation over two orders of magnitude in each direction. The correlations of the immunologic properties of tumor cell cultures with the conventional classification of tumors (histology, cytology, staging, grading, presence of metastases, and secondary tumors) are analyzed. The significance of these findings for modulation of local immunity by RCC as well as for patient outcome is discussed.
Collapse
Affiliation(s)
- B Knoefel
- Institute of Clinical Immunology, Friedrich-Schiller-University, Jena, Germany
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Junker U, Escaich S, Plavec I, Baker J, McPhee F, Rose JR, Craik CS, Böhnlein E. Intracellular expression of human immunodeficiency virus type 1 (HIV-1) protease variants inhibits replication of wild-type and protease inhibitor-resistant HIV-1 strains in human T-cell lines. J Virol 1996; 70:7765-72. [PMID: 8892897 PMCID: PMC190846 DOI: 10.1128/jvi.70.11.7765-7772.1996] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The enzymatic activity of the human immunodeficiency type 1 (HIV-1) protease (PR) is crucial to render HIV-1 virions mature and infectious. Hence, genetic intervention strategies based on trans-dominant (td) variants of the HIV-1 PR might be an alternative to current pharmacological and gene therapy regimens for AIDS. CD4-positive human CEM-SS T-cell lines were generated which constitutively expressed HIV-1 td PR variants. HIV-1 infection experiments demonstrated severely reduced HIV-1 replication in these td PR CEM-SS cell lines compared with control T cells expressing wild-type PR. Furthermore, replication of an HIV-1 isolate bearing a PR inhibitor-resistant PR was blocked, showing that genetic intervention strategies based on td PRs can be effective against HIV-1 isolates containing PR inhibitor-resistant mutants.
Collapse
Affiliation(s)
- U Junker
- Progenesys Program at Systemix, Palo Alto, California 94304, USA
| | | | | | | | | | | | | | | |
Collapse
|
50
|
Junker U, Bevec D, Barske C, Kalfoglou C, Escaich S, Dobrovnik M, Hauber J, Böhnlein E. Intracellular expression of cellular eIF-5A mutants inhibits HIV-1 replication in human T cells: a feasibility study. Hum Gene Ther 1996; 7:1861-9. [PMID: 8894678 DOI: 10.1089/hum.1996.7.15-1861] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Previously, we described two mutants of the cellular Rev co-factor, eukaryotic initiation factor 5A (eIF-5A M13 and M14), which suppress human immunodeficiency virus type 1 (HIV-1) SF2 replication in clonal T cell lines. This study introduced the notion that it is possible to develop gene therapies against infectious agents on the basis of mutant host factors required for viral replication. In this report, we provide further evidence to support this new paradigm and describe murine leukemia virus (MLV)-based retroviral vectors expressing three different eIF-5A mutants from the viral long terminal repeat (LTR). HIV-1 replication (SF2, HXB-3) was reduced up to 2 orders of magnitude in transduced, polyclonal T cell populations. All eIF-5A mutants also showed antiviral activity (approximately seven-fold reduction) in a chronic HIV-1 infection model. Expression of eIF-5A mutant M13 delta in peripheral blood lymphocytes (PBLs) showed no difference in proliferation and metabolic activity as determined in a 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT)-assay, suggesting that expression of this type of mutant protein is not associated with cellular toxicity. In summary, these data suggest that gene therapy for HIV-1 infection can be developed on the basis of mutants of the Rev co-factor eIF-5A.
Collapse
Affiliation(s)
- U Junker
- Progenesys program at Systemix, Palo Alto, CA 94304
| | | | | | | | | | | | | | | |
Collapse
|